美国研究人员9月15日说，血液中3种蛋白质可以“提早”显现肺癌，比癌症症状显露时间早大约一年。
美国弗雷德·哈钦森癌症研究中心研究人员在一年时间里，检验了170名吸烟或曾经吸烟者的血液样本，其中85人被诊断患有癌症，85人没有患癌症。
结果发现，患有癌症的测试对象中，51%的人血液中含有annexin1、14—3—3θ和LAMR1三种蛋白质。
研究中心教授米尔·哈奈什说：“这是关键的一步，这说明，实际上，某些抗原确实在诊断出肺癌前就开始活跃。这时，主体还没有任何症状。”
哈奈什说，5年内有望开发出血液检测肺癌的方法。
“患癌症过程中，免疫系统识别出肿瘤抗原这种外来蛋白质，”哈奈什说，“免疫系统认为这些是异常蛋白质，会对它们作出反应。”
研究结果发表在最新一期《临床肿瘤学杂志》（Journal of Clinical Oncology）上。（生物谷Bioon.com）
生物谷推荐原始出处：
Journal of Clinical Oncology，10.1200/JCO.2008.16.2388，Ji Qiu，Samir M. Hanash
Occurrence of Autoantibodies to Annexin I, 14-3-3 Theta and LAMR1 in Prediagnostic Lung Cancer Sera
Ji Qiu,* Gina Choi, Lin Li, Hong Wang, Sharon J. Pitteri, Sandra R. Pereira-Faca, Alexei L. Krasnoselsky, Timothy W. Randolph, Gilbert S. Omenn, Cim Edelstein, Matt J. Barnett, Mark D. Thornquist, Gary E. Goodman, Dean E. Brenner, Ziding Feng, and Samir M. Hanash
Purpose: We have implemented a high throughput platform for quantitative analysis of serum autoantibodies, which we have applied to lung cancer for discovery of novel antigens and for validation in prediagnostic sera of autoantibodies to antigens previously defined based on analysis of sera collected at the time of diagnosis.
Materials and Methods: Proteins from human lung adenocarcinoma cell line A549 lysates were subjected to extensive fractionation. The resulting 1,824 fractions were spotted in duplicate on nitrocellulose-coated slides. The microarrays produced were used in a blinded validation study to determine whether annexin I, PGP9.5, and 14-3-3 theta antigens previously found to be targets of autoantibodies in newly diagnosed patients with lung cancer are associated with autoantibodies in sera collected at the presymptomatic stage and to determine whether additional antigens may be identified in prediagnostic sera. Individual sera collected from 85 patients within 1 year before a diagnosis of lung cancer and 85 matched controls from the Carotene and Retinol Efficacy Trial (CARET) cohort were hybridized to individual microarrays.
Results: We present evidence for the occurrence in lung cancer sera of autoantibodies to annexin I, 14-3-3 theta, and a novel lung cancer antigen, LAMR1, which precede onset of symptoms and diagnosis.
Conclusion: Our findings suggest potential utility of an approach to diagnosisof lung cancer before onset of symptoms that includes screening for autoantibodies to defined antigens.
